OTCMKTS:DSRLF

DiaSorin Stock Forecast, Price & News

$180.73

+14.92 (+9.00 %)

(As of 04/13/2021 12:00 AM ET)

Add

Compare

Today's Range

$180.73

Now: $180.73▼

$180.73

50-Day Range

$165.00

MA: $186.55▼

$219.00

52-Week Range

$0.00

Now: $180.73▼

$232.00

Volume1 shs

Average Volume279 shs

Market Capitalization$10.11 billion

P/E Ratio50.34

Dividend YieldN/A

Beta0.59

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. The company offers testing kits for infectious diseases, such as gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-hematology, and autoimmunity. It also provides various immunodiagnostic platforms, including LIAISON XL, LIAISON XS, LIAISON QuantiFERON TB Gold PLUS, LIAISON Elastase-1, and LIAISON MDX. The company sells its products directly, as well as through an international network of independent distributors. DiaSorin S.p.A. has collaboration with QIAGEN to develop an ultra-sensitive diagnostic test for Lyme disease. The company was founded in 1968 and is headquartered in Saluggia, Italy.

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Private households

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:DSRLF

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.diasoringroup.com

Phone390-161-4871

Employees1,876

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio3.91

Quick Ratio2.63

Price-To-Earnings

Trailing P/E Ratio50.34

Forward P/E Ratio32.39

P/E GrowthN/A

Sales & Book Value

Annual Sales$791.17 million

Price / Sales12.78

Cash Flow$4.22 per share

Price / Cash Flow42.78

Book Value$16.99 per share

Price / Book10.64

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares55,950,000

Market Cap$10.11 billion

Next Earnings Date5/5/2021 (Estimated)

OptionableNot Optionable

Headlines

DiaSorin S.p.A. (OTCMKTS:DSRLF) Receives Average Rating of "Sell" from Analysts
April 14, 2021 | americanbankingnews.com

Luminex (LMNX) to Get Acquired by DiaSorin for Around $1.8B
April 13, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Luminex Corporation Buyout
April 12, 2021 | finance.yahoo.com

DiaSorin To Buy Luminex For $1.8 Bln
April 12, 2021 | markets.businessinsider.com

Shareholder Alert: Ademi LLP investigates whether Luminex Corporation has obtained a Fair Price in its transaction with DiaSorin
April 12, 2021 | finance.yahoo.com

Luminex Jumps on $1.8 Billion Pact to Be Bought by DiaSorin
April 12, 2021 | msn.com

UPDATE 1-Shares in Italy's DiaSorin jump after $1.8 bln Luminex acquisition
April 12, 2021 | finance.yahoo.com

DiaSorin to Buy Covid-19 Test Maker Luminex for $1.8 Billion
April 11, 2021 | bloomberg.com

Berenberg Bank Reaffirms Hold Rating for DiaSorin (OTCMKTS:DSRLF)
March 24, 2021 | americanbankingnews.com

DiaSorin S.p.A. (OTCMKTS:DSRLF) Given Average Rating of "Sell" by Analysts
March 20, 2021 | americanbankingnews.com

DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q4 2020 Results - Earnings Call Transcript
March 13, 2021 | seekingalpha.com

DiaSorin S.p.A. reports FY results
March 11, 2021 | seekingalpha.com

DiaSorin Weighs Diagnostics Deal for Luminex
February 25, 2021 | msn.com

DiaSorin S.p.A. 2020 Q3 - Results - Earnings Call Presentation
November 13, 2020 | seekingalpha.com

Display Dielectric Materials Market Trends to Expand Significantly by 2027 | DiaSorin S.p.A, Becton, Dickinson and Company, SA Scientific
November 11, 2020 | marketwatch.com

Generex Sees Way Forward With Long-Lasting COVID-19 Vaccine
November 4, 2020 | seekingalpha.com

Diasorin S.p.A. (DSRLF)
October 16, 2020 | nasdaq.com

DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
September 8, 2020 | finance.yahoo.com

InMode (INMD) Surges: Stock Moves 10.6% Higher
July 14, 2020 | finance.yahoo.com

Earnings Update: DiaSorin S.p.A. (BIT:DIA) Just Reported And Analysts Are Boosting Their Estimates
May 16, 2020 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

0.78 out of 5 stars

Medical Sector

1205th out of 2,019 stocks

Private Households Industry

208th out of 378 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for DiaSorin.

2.0 Community Rank

Outperform Votes
DiaSorin has received 71 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
DiaSorin has received 105 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
DiaSorin has received 59.66% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about DiaSorin and other stocks. Vote “Outperform” if you believe DSRLF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DSRLF will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
DiaSorin does not currently pay a dividend.
Dividend Growth
DiaSorin does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, DiaSorin insiders have not sold or bought any company stock.

1.9 Earnings and Valuation

Earnings Growth
Earnings for DiaSorin are expected to grow by 63.08% in the coming year, from $5.58 to $9.10 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of DiaSorin is 50.34, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.42.
Price to Earnings Ratio vs. Sector
The P/E ratio of DiaSorin is 50.34, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 43.99.
Price to Book Value per Share Ratio
DiaSorin has a P/B Ratio of 10.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$180.73

+14.92 (+9.00 %)

(As of 04/13/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive DSRLF News and Ratings via Email

Sign-up to receive the latest news and ratings for DSRLF and its competitors with MarketBeat's FREE daily newsletter.

DiaSorin (OTCMKTS:DSRLF) Frequently Asked Questions

Is DiaSorin a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaSorin in the last year. There are currently 4 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" DiaSorin stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSRLF, but not buy additional shares or sell existing shares.
View analyst ratings for DiaSorin or view top-rated stocks.

What stocks does MarketBeat like better than DiaSorin?

Wall Street analysts have given DiaSorin a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DiaSorin wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is DiaSorin's next earnings date?

DiaSorin is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for DiaSorin.

How has DiaSorin's stock been impacted by Coronavirus (COVID-19)?

DiaSorin's stock was trading at $122.5186 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DSRLF stock has increased by 47.5% and is now trading at $180.7333.
View which stocks have been most impacted by COVID-19.

Who are DiaSorin's key executives?

DiaSorin's management team includes the following people:

Mr. Carlo Rosa, CEO, GM & Exec. Director (Age 55)
Dr. Chen Menachem Even, Chief Commercial Officer, Sr. Corp. VP of Commercial Operations & Exec. Director (Age 58)
Mr. Piergiorgio Pedron, Corp. Accounting Documents Officer, CFO & Sr. Corp. VP (Age 50)
Mr. Riccardo Fava, Sr. Director of Investor Relations & Corp. Communication
Mr. Marco Minolfo, Mang. of the Corp. Legal Affairs Department
Mr. Stefano Ronchi, Sr. Corp. VP of HR (Age 61)
Mr. Ugo Gay, Sr. Corp. VP of Industrial Operations (Age 56)
Mr. John D. Gerace, Pres of DiaSorin Molecular LLC

Who are some of DiaSorin's key competitors?

Some companies that are related to DiaSorin include Vestas Wind Systems A/S (VWDRY), Compass Group (CMPGY), Sands China (SCHYY), Flutter Entertainment (PDYPY), Kuehne + Nagel International (KHNGY), Seven & i (SVNDY), Sandvik AB (publ) (SDVKY), H & M Hennes & Mauritz AB (publ) (HNNMY), Japan Tobacco (JAPAY), Experian (EXPGY), Techtronic Industries (TTNDY), ASSA ABLOY AB (publ) (ASAZY), Amadeus IT Group (AMADY), CK Hutchison (CKHUY) and Swire Pacific (SWRAY).
View all of DSRLF's competitors.

What is DiaSorin's stock symbol?

DiaSorin trades on the OTCMKTS under the ticker symbol "DSRLF."

How do I buy shares of DiaSorin?

Shares of DSRLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DiaSorin's stock price today?

One share of DSRLF stock can currently be purchased for approximately $180.73.

How much money does DiaSorin make?

DiaSorin has a market capitalization of $10.11 billion and generates $791.17 million in revenue each year. The company earns $196.82 million in net income (profit) each year or $3.59 on an earnings per share basis.

How many employees does DiaSorin have?

DiaSorin employs 1,876 workers across the globe.

What is DiaSorin's official website?

The official website for DiaSorin is www.diasoringroup.com.

Where are DiaSorin's headquarters?

DiaSorin is headquartered at Via Crescentino, Saluggia L6, 13040.

How can I contact DiaSorin?

DiaSorin's mailing address is Via Crescentino, Saluggia L6, 13040. The company can be reached via phone at 390-161-4871 or via email at [email protected]

This page was last updated on 4/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here